Proton-Pump Inhibitor (No. II) Lawsuit (MDL-2789) — Eligibility, Settlement Updates, and How to File

Proton-pump inhibitor (no. ii) lawsuit claims allege that popular heartburn medications caused serious kidney damage. Thousands of patients took drugs like Nexium, Prilosec, Prevacid, and Protonix for acid reflux. Many later developed chronic kidney disease or kidney failure. The proton-pump inhibitor (no. ii) lawsuit consolidates these claims into a single federal proceeding. This multidistrict litigation aims to hold pharmaceutical manufacturers accountable for failing to warn consumers about serious health risks.

Case Timeline

Last checked: July 10, 2026

Advertisement

  • July 10, 2026 (Case Status): As of June 2026, 11,321 PPI lawsuits remain active in MDL-2789 before Judge Claire C. Cecchi in the District of New Jersey, with 653 cases resolved during 2025. (Court Record)
  • July 10, 2026 (Case Status): Total PPI filings have grown to 18,706 as of May 2026, with 11,322 cases still active while the settlement process proceeds. (Court Record)
  • July 10, 2026 (Settlement): AstraZeneca’s $425 million Nexium/Prilosec settlement is now in the distribution phase in 2026, with some claimants expected to receive payments before year-end, though Takeda and Procter & Gamble have not joined a global settlement. (Court Record)
  • July 10, 2026 (Bellwether Date): No new 2026 bellwether trial date has been scheduled; the MDL remains in settlement/resolution posture following the vacated October 2023 (AstraZeneca) and October 2024 (Conaway v. Takeda) trial settings. (Court Record)
  • June 02, 2026: PPI Lawsuit Updates 2026: Settlements, Claims & Payouts – lawfold.com (lawfold.com)
  • March 27, 2026: Depo-Provera Lawsuit Update: Leadership Reappointed in Meningioma MDL Cases – Anapol Weiss (Anapol Weiss)
  • June 26, 2026 (Case Status): As of June 2026, 11,321 active PPI lawsuits remain pending in MDL-2789 in the District of New Jersey, down from 18,706 total filed as the settlement process winds down. (Court Record)
  • June 26, 2026 (Settlement): The MDL is nearing resolution in early 2026 with total settlements exceeding half a billion dollars after AstraZeneca’s $425M (Nexium/Prilosec) deal and Takeda payouts, with claims administration now actively verifying eligible plaintiffs. (Court Record)
  • June 26, 2026 (Bellwether Date): No new 2026 bellwether trial has been scheduled; bellwether proceedings remain stayed after the October 2023 settlement halted the first trial and the Conaway v. Takeda October 2024 trial. (Court Record)
  • June 12, 2026 (Settlement): AstraZeneca’s $425M settlement (Nexium/Prilosec, ~11,000 cases) from October 2023 remains in claims administration phase with payouts actively being verified and processed. (Court Record)
  • June 12, 2026 (Case Status): As of May 2026, 11,322 active federal PPI lawsuits remain pending in MDL-2789 in the District of New Jersey; approximately 39% of total cases (18,706 filed) have been resolved. (Court Record)
  • June 12, 2026 (Case Status): 653 cases were resolved in 2025, showing steady but slow progress toward final resolution. (Court Record)
  • June 12, 2026 (Settlement): Takeda Pharmaceuticals and Procter & Gamble have NOT agreed to a global settlement — outstanding claims against non-AstraZeneca defendants remain unresolved. (Court Record)
  • June 12, 2026 (Other): Presiding Judge Claire C. Cecchi continues to oversee MDL-2789 in the U.S. District Court for the District of New Jersey. (Court Record)
  • June 12, 2026 (Bellwether Date): No new bellwether trial dates for 2026 were found in public sources; the original bellwether was preempted by AstraZeneca’s October 2023 settlement announcement. (Court Record)
  • June 05, 2026 (Settlement): MDL-2789 litigation nearing resolution as of early 2026, with total settlements exceeding $500 million across major manufacturers including AstraZeneca and Takeda. (Court Record)
  • June 05, 2026 (Case Status): As of May 2026, 11,322 active PPI lawsuits remain pending in MDL-2789 out of 18,706 total filed, with claims administration actively verifying eligible plaintiffs. (Court Record)
  • June 05, 2026 (Settlement): AstraZeneca’s $425 million settlement (October 2023) covering ~11,000 Nexium and Prilosec claims continues through the claims administration and payout phase. (Court Record)
  • June 05, 2026 (Case Status): MDL-2789 remains consolidated in the District of New Jersey under Judge Claire C. Cecchi, with litigation ongoing against remaining defendants including Takeda and Procter & Gamble who have not agreed to a global settlement. (Court Record)
  • June 05, 2026 (Bellwether Date): No new bellwether trials are scheduled for 2026; the litigation focus has shifted from trial preparation to settlement claims administration following the October 2023 AstraZeneca settlement. (Court Record)
  • June 05, 2026 (Other): Plaintiffs’ claims center on kidney injuries (acute interstitial nephritis, chronic kidney disease, end-stage renal disease) from PPI drugs including Nexium, Prilosec, Prevacid, and Dexilant. (Court Record)
  • October 05, 2023: Plaintiffs’ Attorneys in Heartburn Drugs Lawsuits Announce $425M AstraZeneca Settlement But Say the Fight Is Not Over – Levin Papantonio (Levin Papantonio)
  • October 03, 2023: AstraZeneca settles Nexium and Prilosec product liability litigations – AstraZeneca (AstraZeneca)
  • November 12, 2024: Prevacid Lawsuit | Kidney Disease & Injury | Connect with a Lawyer – consumersafety.org (consumersafety.org)
  • May 22, 2026 (Case Status): As of February 2026, 11,322 active PPI lawsuits remain pending in MDL-2789 in the District of New Jersey (Judge Claire C. Cecchi), out of 18,706 total filed, with approximately 39% of cases resolved. (Court Record)
  • May 22, 2026 (Settlement): The AstraZeneca $425 million settlement (announced October 2023) covering ~11,000 Nexium and Prilosec claims continues processing, with full payouts expected to stretch into 2026-2027. (Court Record)
  • May 22, 2026 (Settlement): Takeda Pharmaceuticals (maker of Prevacid/Dexilant) and Procter & Gamble have NOT reached any global settlement, leaving thousands of claims unresolved against non-AstraZeneca defendants. (Court Record)
  • May 22, 2026 (Case Status): 653 cases were resolved through settlements and dismissals during 2025, showing steady but slow case resolution in this mature MDL. (Court Record)
  • May 22, 2026 (Other): New PPI lawsuits continue to be filed and consolidated into MDL-2789, with kidney injury claims (acute interstitial nephritis, chronic kidney disease, end-stage renal disease) remaining the primary allegations. (Court Record)
  • April 19, 2018: PPI Lawsuit: Prilosec, Nexium, Prevacid, Dexilant Lawsuits – Drugwatch.com (Drugwatch.com)
  • December 17, 2025: Federal Court Creates New MDL for Ozempic and Other GLP-1 Drugs Linked to Vision Loss (NAION) – Levin Papantonio (Levin Papantonio)
  • May 15, 2026 (Case Status): As of early 2026, 11,322 active PPI lawsuits remain pending in MDL-2789 in the District of New Jersey before Judge Claire C. Cecchi, with approximately 39% of total cases (18,706 filed) resolved. (Court Record)
  • May 15, 2026 (Settlement): AstraZeneca’s $425 million settlement (Nexium/Prilosec, ~11,000 plaintiffs) is being administered, with initial payouts expected late-2025 through early-2026 and full distribution extending into 2026. (Court Record)
  • May 15, 2026 (Settlement): Takeda Pharmaceuticals (Prevacid/Dexilant) has NOT reached a settlement and remains an active defendant; plaintiffs continue pursuing claims against Takeda. (Court Record)
  • May 15, 2026 (Case Status): 653 cases were resolved in 2025; defense attorneys for major manufacturers have moved toward structured settlement frameworks rather than continued litigation. (Court Record)
  • May 15, 2026 (Bellwether Date): No new bellwether trial dates have been scheduled for 2026; the Conaway v. Takeda trial (originally set for October 2024) was stayed by court text order, and all pending deadlines remain stayed until further order. (Court Record)
  • May 15, 2026 (Ruling): Judge Cecchi issued a text order staying all pending deadlines in the MDL until further order of the Court, including all proceedings for Conaway v. Takeda Pharma. (Court Record)
  • May 15, 2026 (Settlement): Individual settlement payout estimates range from $20,000 to $150,000+ depending on severity of kidney injury (acute interstitial nephritis, CKD, ESRD). (Court Record)
  • What Is the Proton-Pump Inhibitor (No. Ii) Lawsuit About?

    MDL Detail Current Data
    MDL Number MDL-2789
    Pending Cases 11,321
    Presiding Judge TBD
    Federal District TBD
    Data Source U.S. Judicial Panel on Multidistrict Litigation
    Last Updated July 06, 2026

    Proton-pump inhibitors (PPIs) are among the most widely prescribed medications in the United States. Brand names include Nexium, Prilosec, Prevacid, Protonix, and Dexilant. Doctors prescribe them for gastroesophageal reflux disease (GERD), ulcers, and chronic heartburn. However, research has linked long-term PPI use to severe kidney injuries. Plaintiffs in the proton-pump inhibitor (no. ii) lawsuit allege that manufacturers knew about these risks. They claim drug makers failed to provide adequate warnings to patients and doctors.

    The primary injuries alleged include acute interstitial nephritis, acute kidney injury, and chronic kidney disease. Some patients developed end-stage renal disease requiring dialysis or transplant. A 2016 study in JAMA Internal Medicine found PPI users faced a 28 to 50 percent higher risk of chronic kidney disease. A separate study found a 96 percent increased risk of kidney failure among long-term PPI users. These findings form the scientific backbone of the litigation.

    Key defendants include AstraZeneca, Takeda Pharmaceuticals, Pfizer, Procter & Gamble, and GlaxoSmithKline. Plaintiffs argue these companies prioritized profits over patient safety. In most cases, the claims center on the failure to warn about kidney risks before the FDA required label changes in December 2014. Even after that warning, plaintiffs contend the labels remained inadequate.

    MDL Case Status and Key Facts

    Detail Information
    MDL Number 2789
    Full Title Proton-Pump Inhibitor Products Liability Litigation (No. II)
    Presiding Judge Judge Claire C. Cecchi
    Federal District District of New Jersey
    Approximate Pending Cases 11,322
    Total Cases Filed Approximately 18,700
    Bellwether Trial Status No trial completed; settlement reached before first scheduled trial

    The proton-pump inhibitor (no. ii) lawsuit was consolidated in the District of New Jersey. Judge Claire Cecchi oversees all federal PPI kidney injury claims. As a result, approximately 11,322 cases remain active as of early 2026. Roughly 7,400 additional cases have been resolved through settlements or dismissals. The court has issued over 100 case management orders to guide the litigation.

    A bellwether trial was originally scheduled for October 2023. However, a major settlement was announced just days before trial. No new bellwether trial dates have been set for 2025 or 2026. The litigation is currently in a claims administration phase. A parallel state court proceeding also runs in New Jersey’s Atlantic County under Judge Danielle J. Walcoff.

    Who Qualifies for the Proton-Pump Inhibitor (No. Ii) Lawsuit?

    You may qualify for the proton-pump inhibitor (no. ii) lawsuit if you took a PPI medication and later developed kidney problems. Qualifying medications include Nexium, Prilosec, Prevacid, Protonix, Dexilant, and Aciphex. Both prescription and over-the-counter versions are included. Typically, claimants used these drugs for extended periods before their diagnosis.

    Qualifying injuries generally include acute kidney injury, chronic kidney disease, acute interstitial nephritis, and end-stage renal disease. You might be eligible if you received a kidney-related diagnosis after taking PPIs. Medical records linking your PPI use to your kidney condition are important. For example, hospital records, prescription history, and nephrologist reports strengthen a claim. A licensed attorney can evaluate whether your specific situation meets the criteria.

    The timing of your diagnosis matters as well. Most claims involve PPI use that began before manufacturers updated their warning labels. However, claims may still be valid for later use if warnings remained inadequate. Each state applies different rules for when the filing deadline begins. Consulting an attorney promptly helps protect your right to file.

    How to File a Proton-Pump Inhibitor (No. Ii) Lawsuit Claim

    Filing a proton-pump inhibitor (no. ii) lawsuit claim begins with consulting a mass tort attorney. Most attorneys handling PPI cases offer free case evaluations. They work on a contingency fee basis. This means you typically pay nothing upfront. The attorney reviews your medical history and PPI usage to determine eligibility.

    If your case qualifies, your attorney files a complaint in the MDL or an appropriate state court. You will need to complete a Plaintiff Fact Sheet. This document details your medical history, PPI usage, and injuries. The court uses these fact sheets to organize and evaluate claims. As a result, accuracy and completeness are critical when filling out this form.

    Statute of limitations deadlines vary by state. Most states allow one to three years from the date you discovered your injury. The discovery rule is particularly important in PPI cases. Many patients did not learn about the PPI-kidney connection until years after their diagnosis. However, waiting too long can bar your claim entirely. An experienced attorney can advise you on your state’s specific deadline.

    📨 Get Free Mass Tort Guides Alerts

    Free · No spam · Unsubscribe anytime

    Settlement Updates and What to Expect

    The proton-pump inhibitor (no. ii) lawsuit has seen significant settlement activity. In October 2023, a major settlement was reached with AstraZeneca covering Nexium and Prilosec kidney claims. Additional settlements followed with Takeda, Pfizer, Procter & Gamble, and GlaxoSmithKline. The combined settlement value across all defendants reportedly exceeds half a billion dollars. Individual payout amounts vary based on several factors.

    Settlement distributions are currently being processed. Plaintiffs who submitted their Plaintiff Fact Sheets on time are in the claims review process. Initial payouts began in late 2025 and early 2026. Full distribution may extend into 2027. The amount each plaintiff receives depends on injury severity, duration of PPI use, and medical documentation. Cases involving kidney failure or dialysis typically receive higher compensation than those involving less severe kidney impairment.

    No bellwether trial has gone to verdict in this proton-pump inhibitor (no. ii) lawsuit. Settlements were reached before any jury decision. For plaintiffs still considering filing, the settlement process remains ongoing. However, deadlines exist for submitting required documentation. An attorney familiar with the MDL can help determine if new claims are still being accepted.

    State-by-State Considerations

    State laws significantly affect proton-pump inhibitor (no. ii) lawsuit claims. Each state has its own statute of limitations, damage caps, and product liability rules. For example, New Jersey has seen the highest concentration of PPI cases due to hosting both the federal MDL and a state multicounty litigation. California and Pennsylvania also have notable plaintiff counts. States like Texas and Florida apply tort reform laws that may cap certain damages.

    Some states apply a one-year filing deadline while others allow up to three years. Damage caps in certain states limit non-economic compensation. In most cases, your attorney will file in the jurisdiction most favorable to your claim. You can learn more about how your state’s laws affect mass tort claims on our state-by-state tort reform guide.

    Frequently Asked Questions

    Is there still time to file a proton-pump inhibitor (no. ii) lawsuit claim?

    It depends on your state’s statute of limitations and when you discovered your injury. Some filing windows may still be open under the discovery rule. Consulting a licensed attorney as soon as possible is the best way to determine your eligibility.

    What types of kidney injuries qualify for this lawsuit?

    Qualifying injuries typically include acute kidney injury, chronic kidney disease, acute interstitial nephritis, and end-stage renal disease. Bone fractures and stomach cancer have also been alleged in some cases. Medical documentation connecting your injury to PPI use is essential.

    How long does it take to receive a settlement payout?

    Settlement timelines vary depending on case complexity and claims processing. The proton-pump inhibitor (no. ii) lawsuit settlements are currently being distributed. Some plaintiffs have already received initial payments, while others may wait until 2027 for full distribution. Your attorney can provide a timeline specific to your claim.

    Check If You May Qualify

    Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.

    Official Sources & Resources

    For verified mass tort and MDL information:

    Content last reviewed May 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.

    Related Guides

    Going through divorce too? Compare state laws at Divorce Help Guide. Affected by a recalled drug as a Medicare patient? See Medicare Cover Guide. Just diagnosed with a serious illness? Compare life insurance at Life Insure Guide. PFAS in your water? Check homeowners coverage at Home Insure Guide.